Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

927 questions · 1,014 findings · 29 reviews · Oral medicine and oral cancer

No studies found 123 · 12.1%GRADE not reported 604 · 59.6%Very low 193 · 19%Low 58 · 5.7%Moderate 35 · 3.5%High 1 · 0.1%

Topical clobetasol propionate 0.025% vs clobetasol cream 0.05% cream

Partial response (partial or complete response) · People with erosive oral lichen planus

Topical clobetasol propionate 0.025% showed no clear difference in partial response (partial or complete response) compared with topical clobetasol propionate 0.05%; GRADE not reported.

1 finding from 1 review

Tacrolimus 0.1% vs Topical clobetasol propionate 0.05% ointment

Reduction in target/mean lesion size · People with erosive oral lichen planus

Topical tacrolimus 0.1% ointment showed no clear difference in reduction in target/mean lesion size compared with topical clobetasol propionate 0.05% ointment; GRADE not reported.

1 finding from 1 review

Clobetasol-17-propionate 0.025% lipid-loaded microspheres vs Clobetasol propionate 0.025% ointment

Pain reduction (VAS 0-100) · People with erosive oral lichen planus

Clobetasol-17-propionate 0.025% lipid-loaded microspheres led to lower pain reduction (VAS 0-100) compared with conventional 0.025% clobetasol lipophilic ointment in hydrophilic…; GRADE not reported.

1 finding from 1 review

Surgery vs Radiotherapy alone

Adverse events associated with treatment · Adults with oropharyngeal cancer
1 finding from 1 review

COE with blood/salivary (biomarker) analysis vs Reference standard: examination and clinical evaluation by a physician/clinician with specialist knowledge or training (long-term follow-up accepted for those screened negative)

Outcome not reported · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance programme, or screened…

The review found no eligible studies for this question.

1 finding from 1 review

COE with light-based detection (e.g. ViziLite Plus, Microlux/DL, VELscope, Identafi 3000) vs COE with vital rinsing (toluidine blue/tolonium chloride)

Outcome not reported · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance programme, or screened…

The review found no eligible studies for this question.

1 finding from 1 review

COE with blood/salivary (biomarker) analysis vs COE with vital rinsing (toluidine blue/tolonium chloride)

Outcome not reported · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance programme, or screened…

The review found no eligible studies for this question.

1 finding from 1 review

COE with light-based detection (e.g. ViziLite Plus, Microlux/DL, VELscope, Identafi 3000) vs Reference standard: examination and clinical evaluation by a physician/clinician with specialist knowledge or training (long-term follow-up accepted for those screened negative)

Outcome not reported · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance programme, or screened…

The review found no eligible studies for this question.

1 finding from 1 review

COE with vital rinsing (toluidine blue/tolonium chloride) vs Reference standard: examination and clinical evaluation by a physician/clinician with specialist knowledge or training (long-term follow-up accepted for those screened negative)

Outcome not reported · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance programme, or screened…

The review found no eligible studies for this question.

1 finding from 1 review

COE with blood/salivary (biomarker) analysis vs COE with light-based detection (e.g. ViziLite Plus, Microlux/DL, VELscope, Identafi 3000)

Outcome not reported · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance programme, or screened…

The review found no eligible studies for this question.

1 finding from 1 review

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

Normalcy of diet (mean worst ability to eat, 1 to 4 scale) · Adults with cancer receiving treatment

Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in normalcy of diet (mean worst ability to eat, 1 to 4 scale) compared with placebo; GRADE not reported.

1 finding from 1 review